Genentech

Stock quotes

DJIA	10611.84	+44.51
NASDAQ	2368.46	+0.00
S&P 500	1150.24	+0.00
AA	13.64	+0.00
AXP	40.11	+0.00
BA	70.07	+0.00
BAC	17.12	+0.00
CAT	58.90	+0.00
CSCO	25.97	+0.00
CVX	73.99	+0.00
DD	35.35	+0.00
DIS	33.81	+0.00
GE	16.48	+0.00
HD	32.13	+0.00
HPQ	52.02	+0.00
IBM	127.60	+0.00
INTC	21.25	+0.00
JNJ	64.22	+0.00
JPM	43.18	+0.00
KFT	29.42	+0.00
KO	53.60	+0.00
MCD	65.21	+0.00
MMM	81.26	+0.00
MRK	36.88	+0.00
MSFT	29.18	+0.00
PFE	17.29	+0.00
PG	63.17	+0.00
T	25.60	+0.00
TRV	53.62	+0.00
UTX	72.04	+0.00
VZ	29.84	+0.00
WMT	53.97	+0.00
XOM	67.22	+0.00
CAL	22.82	+0.00
WFT	17.24	+0.00
GS	173.51	+0.00
AFFX	7.98	+0.00
RDY	25.95	+0.00
V	92.74	+0.00
OXY	81.86	+0.00

Topics

Analyst Rating
Dow 30
- 3M
- Alcoa
- American Express
- AT&T
- Bank of America
- Boeing
- Caterpillar
- Chevron
- Cisco Systems
- Coca Cola
- Disney
- Du Pont
- Exxon Mobil
- General Electric
- Hewlett Packard
- Home Depot
- IBM
- Intel
- Johnson & Johnson
- JP Morgan
- Kraft Foods
- McDonalds
- Merck
- Microsoft
- Pfizer
- Procter & Gamble
- Travelers
- United Technologies
- Verizon
- Wal Mart
Industry
Nasdaq 100
- Activision Blizzard
- Adobe Systems
- Akamai Tech
- Altera
- Amazon.com
- Amgen
- Apollo Group
- Apple
- Applied Materials
- Autodesk
- Automatic Data Processing
- Baidu
- Bed Bath & Beyond
- Broadcom
- C.H. Robinson
- CA
- Celgene
- Cephalon
- Cisco Systems
- Cognizant
- Comcast
- Costco Wholesale
- Dell
- DENTSPLY
- DIRECTV
- DISH
- eBay
- Electronic Arts
- Expedia
- Express Scripts
- Fastenal
- First Solar
- Fiserv
- Flextronics
- Foster Wheeler
- Garmin
- Genentech
- Genzyme
- Gilead Sciences
- Google
- Henry Schein
- Hologic
- Human Genome Science
- Illumina
- Infosys
- Intel
- Intuit
- Intuitive Surgical
- Joy Global
- Juniper Networks
- Lam Research
- Life Technologies
- Linear Technology
- Logitech
- Marvell Technology
- Maxim Integrated
- Millicom
- NetApp
- Network Appliance
- News Corporation
- NII Holdings
- NVIDIA
- O'Reilly Automotive
- Oracle
- Paychex
- Qualcomm
- Research in Motion
- Ross Stores
- Ryanair
- SanDisk
- Seagate
- Sears Holdings
- Sigma-Aldrich
- Staples
- Starbucks
- Steel Dynamics
- Symantec
- Teva
- Urban Outfitters
- VeriSign
- Vertex Pharmaceuticals
- Warner Chilcott
- Xilinx
- Yahoo
S&P 500
Ticker
Uncategorized

About tradingpattern.net

The movement of a security's price over a specific time period.

dedicated to value creation and applying the scientific method in finance

Search

network

renhe hk 1387 ¤ china electric motor celm ¤ kaufman convergys ¤ nasdaq:extr ¤ tivo upgrade jp morgan ¤ jeffries downgrade of con edison ¤ analyst opinion on qcom on google fi ¤ silverton deutsche bank ¤ pwe upgraded by canaccord adams ¤ aig ¤ dow statistics ¤ textron downgrade ¤ cablevision fee arbitration ¤ analyst opinions on avav ¤ yge upgrade ¤ jesup air tran holdings ¤ cal ¤ blackstone analyst ratings ¤ amln ¤ nyse:cal ¤ hk:1387 ¤ dow jones statistics ¤ bmo capital amylin ¤ visn downgrade ¤ blackstone analysts ratings ¤ visionchina media kurs ¤

credit ¤ research ¤ march ¤ jefferies ¤ hold ¤ boenning ¤ china ¤ bb&t ¤ upgraded ¤ renhe ¤ ubs ¤ commercial ¤ visionchina ¤ motor ¤ for ¤ scattergood ¤ roth ¤ target ¤ jeffries ¤ stock ¤ holdings ¤ deutsche ¤ adams ¤ canaccord ¤ blackstone ¤ amln ¤ cablevision ¤ jesup ¤ morgan ¤ bmo ¤ analyst ¤ opinion ¤ air ¤ downgrade ¤ 2010 ¤ mfa ¤ s&p ¤ downgraded ¤ sachs ¤ sell ¤ bank ¤ price ¤ rating ¤ fee ¤ amylin ¤ capital ¤ securities ¤ recommendation ¤ avav ¤ energy ¤ electric ¤ buy ¤ upgrades ¤ citigroup ¤ goldman ¤ upgrade ¤ disney ¤ ratings ¤ arbitration ¤ downgrades ¤

network - market statistics

network - archived market statistics

High dividend yield stocks

Genentech konkretisiert Jahresprognose

Tuesday, March 18th, 2008

Genentech Inc. hat am Freitag die Ergebnisprognosen für das laufende Fiskaljahr präzisiert. Demnach erwartet Genentech, für das laufende Geschäftsjahr einen Gewinn im Bereich von 3,35 bis 3,45 $ je Aktie, nach 3,30 bis 3,45 $ je Anteilsschein.
Analysten gehen für das laufende Fiskaljahr von einem EPS von 3,43 Dollar sowie einem Umsatz von 13,04 Mrd. [...]

Genentech: Beraterausschuss gegen Zulassung von Avastin gegen Brustkrebs

Thursday, December 6th, 2007

Die amerikanische Genentech Inc., die US-Tochter des schweizerischen Pharmakonzern Roche Holding AG, hat einen Rückschlag erlitten. Ein Beraterausschuss der US-Arzneimittelbehörde FDA hat gegen die Zulassung des Krebsmittels Avastin zur Behandlung von Brustkrebs gestimmt.

tradingpattern.net